This is a preview of subscription content, access via your institution
Relevant articles
Open Access articles citing this article.
-
Advances in the delivery of RNA therapeutics: from concept to clinical reality
Genome Medicine Open Access 27 June 2017
Access options
Subscribe to this journal
Receive 12 print issues and online access
$209.00 per year
only $17.42 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Garber, K. Alnylam terminates revusiran program, stock plunges. Nat Biotechnol 34, 1213–1214 (2016). https://doi.org/10.1038/nbt1216-1213
Published:
Issue Date:
DOI: https://doi.org/10.1038/nbt1216-1213
This article is cited by
-
Reduction of the therapeutic dose of silencing RNA by packaging it in extracellular vesicles via a pre-microRNA backbone
Nature Biomedical Engineering (2020)
-
Advances in oligonucleotide drug delivery
Nature Reviews Drug Discovery (2020)
-
Delivery of RNAi-Based Therapeutics for Bone Regeneration
Current Osteoporosis Reports (2020)
-
The current state and future directions of RNAi-based therapeutics
Nature Reviews Drug Discovery (2019)
-
Alnylam launches era of RNAi drugs
Nature Biotechnology (2018)